Emmanuelle Charpentier

Emmanuelle Charpentier is a leading biochemist and Nobel Laureate known for her co-discovery of the CRISPR/Cas9 gene-editing technology. She has held key research positions at the Max Perutz Labs of the University of Vienna and the Medical University of Vienna, and currently heads the Max Planck Research Unit for the Science of Pathogens in Berlin. She previously served as Director at the Max Planck Institute for Infection Biology. Her work bridges fundamental microbiology and revolutionary biotechnological applications.

Research Interests: Charpentier's work centers on molecular mechanisms of bacterial immunity, particularly the CRISPR/Cas9 system. Her research has unlocked transformative tools in genome editing, enabling precise DNA modifications with applications in gene therapy, disease modeling, and synthetic biology. Her interests span RNA biology, microbial defense systems, and the ethical implications of genetic engineering.

Publications Trends: Her seminal 2011 paper introduced the dual-RNA guided mechanism of Cas9, establishing the foundation for programmable genome editing. This work catalyzed a global shift in molecular biology, with subsequent research expanding into therapeutic development, off-target analysis, and delivery systems for clinical use.

• Nobel Prize in Chemistry (2020) – Shared with Jennifer Doudna
• Breakthrough Prize in Life Sciences (2015)
• Canada Gairdner International Award (2016)
• Wolf Prize in Medicine (2020)
• Leibniz Prize (2016)
• Gruber Genetics Prize (2015)

Grants & Advising: The Austrian Science Fund (FWF) supported her early career with three major research grants during her tenure in Vienna. While specific advisees are not listed, her leadership at Max Perutz Labs and Max Planck Institutes indicates mentorship of doctoral students and postdoctoral researchers. She has led large-scale research programs focused on pathogen science and genome engineering.

Labs and Teams: Charpentier led the research group at the Max Perutz Labs (University of Vienna and Medical University of Vienna), where the tracrRNA was discovered. She now leads the Max Planck Research Unit for the Science of Pathogens in Berlin, directing a multidisciplinary team focused on understanding infectious agents and developing novel antimicrobial strategies using genome-editing insights.